Latest news with #drugmarket
Yahoo
8 hours ago
- Business
- Yahoo
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
Key Points Drugmakers are vying for the oral GLP-1 market, which could soon be worth billions of dollars. Eli Lilly recently disappointed with phase 3 data for its oral GLP-1 candidate, orforglipron. This could enable other companies, such as Novo Nordisk, to capitalize on this market. 10 stocks we like better than Eli Lilly › After crushing the market over the past few years, Eli Lilly (NYSE: LLY) is finally feeling the effects of gravity. The company has faced a pair of setbacks this year. The latest one came when Lilly reported data from a phase 3 study for its investigational oral GLP-1 candidate, orforglipron. Results from this trial were not as strong as investors had hoped, resulting in a significant decline in Eli Lilly's share price. However, several other companies, particularly Eli Lilly's main rival, could benefit from these developments. The promising oral GLP-1 market Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up billions in quarterly sales. Its only real competitor in weight management is Novo Nordisk's (NYSE: NVO) Wegovy. Both therapies are administered subcutaneously once a week. However, many people don't like needles and would prefer oral pills. Additionally, pills are easier and less expensive to manufacture, store, and transport. That's why an oral weight loss medicine that's about as effective as subcutaneous ones could be massively successful. It would offer a significant advantage to patients with its easier delivery method, and also allow drugmakers to ramp up manufacturing and target even more patients. In other words, there's a large untapped market here. There is currently just one oral GLP-1 drug approved by the U.S. Food and Drug Administration: Rybelsus, marketed by Novo Nordisk (and indicated for diabetes). This medicine generated $3.6 billion in sales last year. But according to some estimates, the oral GLP-1 market could hit $20 billion by 2030. Though GLP-1 medicines treat a range of diseases, they may be best known for their effectiveness in diabetes and, in recent years, weight loss. Assuming the oral GLP-1 space does reach the predicted $20 billion by 2030, a significant portion of that total -- perhaps up to half or more -- might be from sales for weight management, given the growing popularity of anti-obesity medicines and the advantages that oral ones would confer. Eli Lilly's setback Eli Lilly had hoped it could cash in on that market thanks to orforglipron. Although the pill performed well in diabetes, it did not meet Wall Street expectations in the first of a pair of phase 3 studies in weight management. The trial enrolled patients who were obese or overweight, but did not have diabetes. Eli Lilly reported that over the 72-week study, orforglipron led to an average reduction of 12.4% in body weight at the highest dose. In a similar 72-week study comparing Zepbound and Wegovy head-to-head, Zepbound led to an average weight loss of 20.2%, compared to Wegovy's 13.7%. Oral and injectable medications don't have the same mechanism of action. The latter are often more effective for various reasons, including the fact that they're absorbed more quickly into the body. Even so, some analysts hoped orforglipron would match the efficacy of subcutaneous GLP-1 medicines in weight management. Others, like those at the healthcare-focused investment management bank Leerink Partners, were hoping for an average weight loss of 14.4% from orforglipron. Novo Nordisk could be a major winner Eli Lilly's biggest competitor in diabetes and weight loss is Novo Nordisk, so it makes sense that the latter's share price jumped following Lilly's recent setback. These developments open the door for Novo Nordisk to catch up to its competitors. The Denmark-based drugmaker had been falling behind due to clinical challenges of its own over the past year. Novo Nordisk has recently initiated phase 3 studies for amycretin, an investigational weight loss medicine, in both subcutaneous and oral formulations. If amycretin proves more effective than orforglipron in phase 3 studies, Novo Nordisk could be one of the biggest winners of the oral GLP-1 space. Several other companies could benefit, too; Viking Therapeutics and Structure Therapeutics are two smaller biotechs also working on oral GLP-1s. Which stock should you buy? My view is that despite its recent setback, Eli Lilly remains a buy. Its financial results are excellent; its GLP-1 portfolio remains strong; and the company has blockbusters in other areas, such as oncology and immunology. Furthermore, Lilly has a robust pipeline, which it's been expanding significantly through acquisitions and licensing agreements. That said, Novo Nordisk's shares are also attractive. The sell-off the company has experienced over the past year appears overdone, as it still holds a strong position in diabetes and weight management, and it boasts exciting candidates in other areas. These two companies both have the potential to deliver strong returns over the long term. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors was originally published by The Motley Fool
News.com.au
5 days ago
- Health
- News.com.au
Latest wastewater report reveals Australians consumed 22 tonnes of illicit drugs over one year
The latest wastewater report has revealed Australians consumed more than 20 tonnes of illicit drugs worth billions of dollars over one year. The report, released by the Australian Criminal Intelligence Commission (ACIC), found 22.2 tonnes of methylamphetamine, cocaine, heroin and MDMA worth an estimated $11.5bn were used by Australians between August 2023 to August 2024. Authorities found cocaine use had risen 69 per cent from the previous year, MDMA use rose 49 per cent, meth use 21 per cent and heroin use rose by 14 per cent. The dramatic rise in drug use was attributed to the recovery of the illicit drug market following Covid-19 restrictions as organised crime groups quickly re-established and expanded their operations to supply markets. ACIC chief executive officer Heather Cook said serious and organised crime remained an enduring threat to Australia's national security and safety. 'Serious and organised crime groups exploit Australia's high demand for illicit drugs and are focused on maximising profit at the expense of the community's security and wellbeing,' she said. 'The 2.2 tonne increase in national meth consumption is concerning because 12.8 tonnes is the highest annual level recorded by the program and the drug causes significant community harm. 'Similarly, there has been a large increase in national cocaine consumption, also to the highest annual level recorded by our wastewater program.' Record high meth, MDA and ketamine consumption was detected in capital cities and record high heroin use was found in regional areas. The average regional consumption of alcohol, nicotine, MDA, methylamphetamine, oxycodone, fentanyl and cannabis exceeded capital city consumption. Ms Cook said wastewater data combined with other drugs-related information helped authorities develop a comprehensive understanding of illicit drug markets. 'This combined data strongly indicates a concerning level of market growth, extending beyond the markets for illicit stimulants,' she said. 'This challenge can only be met though concerted and co-ordinated effort under the three pillars of the National Drug Strategy: demand reduction, supply reduction and harm reduction.' The report found the Northern Territory consumed nicotine and alcohol at rates above the national average. Regional sites South Australia, Western Australia and Victoria had the highest average meth consumption. Adelaide and Perth were the capital cities with the highest meth use, while the highest cocaine use was recorded in Sydney. For free and confidential advice about alcohol and other drug treatment services call the National Alcohol and Other Drug Hotline on 1800 250 015.
Yahoo
16-07-2025
- Business
- Yahoo
[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Ultomiris Drug Market size & share revenue was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach around USD 64.12 Billion by 2034, at a CAGR of 31.52% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are AstraZeneca, Xencor, Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, and others. Austin, TX, USA, July 16, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Ultomiris Drug Market Size, Trends and Insights By Indication (Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)), By End-use (Adult, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of the global Ultomiris Drug Market size & share was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach a value of around USD 64.12 Billion by 2034, at a compound annual growth rate (CAGR) of about 31.52% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Ultomiris Drug Market @ Overview As per the industry experts at CMI, the global ultomiris drug market will witness a whopping CAGR between 2025 and 2034. This could be attributed to the rise in demand for various long-acting treatments for rare disorders, especially paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). North America holds the largest market share due to speedy adoption of ultomiris drug by the U.S. and Canada. Hospital pharmacies dominate as far as distribution channels are concerned. Key Trends & Drivers Long-Acting Treatment Preference to Spell Growth: Ultomiris does offer a long-acting dosing interval (every 8 weeks), which enhances patient convenience and compliance as compared to the shorter-acting alternatives. Ultomiris is also known for demonstrating robust clinical performance along with a well-established safety profile. Request a Customized Copy of the Ultomiris Drug Market Report @ Approval by Regulatory Bodies to Catalyze Growth: The U.S. FDA had approved ultomiris for adults suffering from gMG in the year 2022. Since then, the drug has strengthened its position in the neurology sector. The FDA also conducted a review on priority in March 2024 for ultomiris in NMOSD. These approvals and reviews are bound to take the ultomiris market to the next level in the forecast period. Report Scope Feature of the Report Details Market Size in 2025 USD 5.47 Billion Projected Market Size in 2034 USD 64.12 Billion Market Size in 2024 USD 4.16 Billion CAGR Growth Rate 31.52% CAGR Base Year 2024 Forecast Period 2025-2034 Prominent Players AstraZeneca, Xencor Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, Others, and Others Key Segment By Indication, End-use, Distribution Channel and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Ultomiris Drug report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Ultomiris Drug report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Ultomiris Drug Market Report @ SWOT Analysis Strengths: Ultomiris has demonstrated a manageable safety profile and efficacy in the treatment of gMG and PNH. With the market for rare disease therapies growing on the whole, a favorable environment is created for ultomiris. Also, ongoing research coupled with clinical trials is bound to result in extra approved indications for ultomiris drug, thereby bolstering its market potential. Weaknesses: Ultomiris is quite expensive. This is likely to apply brakes to its accessibility for certain patients, particularly in the resource-limited settings. Moreover, the need for intravenous infusion could be a barrier to patient convenience and preference. Opportunities: Ultomiris has a huge potential for growth in the emerging markets with expansion of healthcare infrastructure and awareness regarding rare diseases. Furthermore, a subcutaneous formulation on the part of ultomiris is likely to offer a convenient route of administration for the patients. Also, exploration of the potential of combining ultomiris with the other therapies for improving treatment outcomes could fetch more revenue. Threats: There are pharmaceutical companies developing competing therapies for gMG and PNH, which is likely to erode the market share of ultomiris. Also, the development as well as the approval of ultomiris' biosimilar version is likely to adversely affect the market pricing and share. Request a Customized Copy of the Ultomiris Drug Market Report @ Key questions answered in this report: What is the size of the Ultomiris Drug market and what is its expected growth rate? What are the primary driving factors that push the Ultomiris Drug market forward? What are the Ultomiris Drug Industry's top companies? What are the different categories that the Ultomiris Drug Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Ultomiris Drug market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Ultomiris Drug Research Report | Fast Delivery Available - [220+ Pages] @ Regional Perspective The ultomiris drug market is classified into North America, Europe, Asia Pacific, and LAMEA. North America North America accounts for more than 40% of the market share, and the status quo is expected to remain unchanged during the forecast period. This could be credited to the U.S. being equipped with advanced diagnostic capabilities, which enable early detection as well as treatment of aHUS and PNH. Switching to ultomiris from soliris is witnessing acceleration, which is supported by the former's dosing intervals. Speedy adoption of innovative therapies and strong clinical trial activity are bolstering the market further. Higher level of awareness amongst the healthcare professionals regarding rare diseases ascertains timely intervention and diagnosis. Preference for therapies with a reduction in treatment burden does favor ultomiris over its counterparts. Asia Pacific The Asia Pacific is expected to expand at the fastest CAGR in the ultomiris market due to the rise in the number of patients with rare diseases. Improvement in healthcare infrastructure does improve access to advanced treatments through diagnosis. The structured approach toward rare disease management in Japan extends support to patient identification as well as treatment initiation. Integrating ultomiris into clinical practice does reflect the perceived benefits. Such elements do contribute to the presence of this drug in Japan. China's expanding healthcare system and emphasis on rare diseases do contribute to the growth of ultomiris market. Efforts in the direction of improving diagnostic capabilities facilitate detection of aHUS and PNH earlier. Moreover, increasing familiarity of healthcare professionals with complement inhibitors lends support to the adoption of the drug. Europe Europe's ultomiris market is strongly supported by growing awareness as well as diagnosis regarding rare diseases. Of late, ultomiris has been approved for pediatric use regarding conditions such as PNH. Clinical recommendations and guidelines do endorse the usage of ultomiris in the patient population. This transition to ultomiris from the existing therapies does reflect the perceived benefits. The region's emphasis on improvement of patient quality of life does support adopting treatments needing lesser hospital visits. LAMEA In LAMEA, physicians are increasingly recommending longer-acting treatment for reducing clinical visits and improving patient compliance. The educational efforts are improving understanding of complement-mediated cases across all the markets. Though regulatory timelines could vary, frequency of approvals is expanding across various countries. partnerships and collaborations in the healthcare sector contribute to the development of the market. Request a Customized Copy of the Ultomiris Drug Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'Ultomiris Drug Market Size, Trends and Insights By Indication (Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)), By End-use (Adult, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Ultomiris Drug Market: AstraZeneca Xencor Inc. Chugai Pharmaceutical Argenx Alexion Pharmaceuticals Others Click Here to Access a Free Sample Report of the Global Ultomiris Drug Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: Pet Oral Care Products Market: Pet Oral Care Products Market Size, Trends and Insights By Product Type (Toothbrush, Toothpaste, Mouthwash/Rinse, Dental Chews, Others), By Animal Type (Dogs, Cats, Others), By Application (Residential, Commercial), By Distribution Channel (Supermarkets and Hypermarkets, Online Stores, Specialized Pet Shops, Veterinary Channels), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Magnesium Supplements Market: Magnesium Supplements Market Size, Trends and Insights By Type (Tablets, Capsules, Powders, Liquids), By Application (Dietary Supplements, Pharmaceuticals, Animal Feed, Others), By Distribution Channel (Online, Offline), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Blockchain-Based Electronic Health Record Market: Blockchain-Based Electronic Health Record Market Size, Trends and Insights By Blockchain Type (Public Blockchain, Private Blockchain, Consortium/Permissioned Blockchain, Hybrid Blockchain), By Application (Patient Record Management, Clinical Trial Data Sharing, E-prescription & Medical Billing, Medical Imaging & Diagnostics, Insurance Claim & Fraud Detection, Remote Patient Monitoring (via IoMT)), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 AI in Synthetic Biology Market: AI in Synthetic Biology Market Size, Trends and Insights By Technology (Gene Synthesis, Genome Editing, Synthetic Biology Tools, Bioinformatics), By Application (Healthcare & Medicine, Agricultural Biotechnology, Industrial Biotechnology, Environmental Biotechnology), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Advanced Genomics Market: Advanced Genomics Market Size, Trends and Insights By Offering (Products, Services), By Technology (Sequencing, PCR, Gene Editing, Flow Cytometry, Microarrays, In Situ Hybridization), By Application (Diagnostics, Drug Discovery and Development, Precision Medicine, Agriculture), By End-user (Hospitals and Clinics, Research Centers, Pharmaceutical and Biotechnology Companies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Cell and Gene Therapy Market: Cell and Gene Therapy Market Size, Trends and Insights By Therapy Type (Cell Theray, Gene Therapy), By Therapeutic Class (Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology, Ophthalmology, Infectious Disease, Neurological Disorders, Others), By Delivery Method (In Vivo, Ex Vivo), By End-User (Hospitals, Cancer Care Centers, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Battery-Free Implants Market: Battery-Free Implants Market Size, Trends and Insights By Product Type (Neural Implants, Cardiac Implants , Cochlear Implants, Orthopedic Implants, Others), By Technology (Energy Harvesting, Wireless Power Transfer, RFID/NFC-based Systems), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Research Institutions, Specialty Clinics), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Alzheimer's Drug Market: Alzheimer's Drug Market Size, Trends and Insights By Type of Drug (Disease-Modifying Therapies (DMTs), Symptomatic Therapies), By Application (Amyloid-Targeting Agents, Tau-Targeting Agents, Cholinesterase Inhibitors, NMDA Antagonists, Other Agents), By End User (Hospitals, Clinics, Home Care Settings), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 The Ultomiris Drug Market is segmented as follows: By Indication Paroxysmal Nocturnal Hemoglobinuria (PNH) Atypical Hemolytic Uremic Syndrome (aHUS) Generalized Myasthenia Gravis (gMG) Neuromyelitis Optica Spectrum Disorder (NMOSD) By End-use Adult Pediatric By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies Click Here to Get a Free Sample Report of the Global Ultomiris Drug Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Ultomiris Drug Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Ultomiris Drug Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Ultomiris Drug Market? What Was the Capacity, Production Value, Cost and PROFIT of the Ultomiris Drug Market? What Is the Current Market Status of the Ultomiris Drug Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Ultomiris Drug Market by Considering Applications and Types? What Are Projections of the Global Ultomiris Drug Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Ultomiris Drug Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Ultomiris Drug Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Ultomiris Drug Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Ultomiris Drug Industry? Click Here to Access a Free Sample Report of the Global Ultomiris Drug Market @ Reasons to Purchase Ultomiris Drug Market Report Ultomiris Drug Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Ultomiris Drug Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Ultomiris Drug Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Ultomiris Drug Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Ultomiris Drug market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Ultomiris Drug Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Ultomiris Drug market analysis. The competitive environment of current and potential participants in the Ultomiris Drug market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Ultomiris Drug market should find this report useful. The research will be useful to all market participants in the Ultomiris Drug industry. Managers in the Ultomiris Drug sector are interested in publishing up-to-date and projected data about the worldwide Ultomiris Drug market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Ultomiris Drug products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Ultomiris Drug Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI offers a comprehensive solution that covers everything from data collection to investment advice. Our company's expert analysis digs out essential factors that help us understand the significance and impact of market dynamics. The professional experts utilize client insights to inform strategies for estimating future declines, forecasting opportunities for growth, and conducting consumer surveys. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Ultomiris Drug Research Report | Fast Delivery Available - [220+ Pages] @
Yahoo
12-07-2025
- Business
- Yahoo
Eli Lilly and Company (LLY): I Would 'Love' If Trump Praised The Company, Says Jim Cramer
We recently published . Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer's morning show. Over the course of this year, the CNBC TV host has maintained that the firm enjoys a lead in the weight loss drug market and aims to further expand its dominance by developing a robust manufacturing base. Cramer also believes that Eli Lilly and Company (NYSE:LLY) will benefit from introducing a weight loss pill along with a strong pipeline of drugs that targets diseases such as hypertension. His recent comments focused on an analyst note: '[On a Mizuho note saying POTUS would praise LLY and JNJ] I would love that, that won't happen. You know why it won't happen? See there's someone in the health and human services department that's not crazy about, about big pharma and the way we think about it. So there's not going to be a party thrown for you at Lilly. You know that GLP-1 is not a favorite of RFK Jr. Not a favorite. So no, no party for them.' Earlier, Cramer discussed Eli Lilly and Company (NYSE:LLY)'s CEO and investor expectations: 'David Ricks, if you spend time with him, has a view, of what should be done, that ends with the pill that you take every day, no shot . . but everyone's thinking that he doesn't have anything in the hopper. He's got heart coming up, he's going to have Alzheimer's coming up, oh buy. An array of pharmaceutical pills with the company's logo on the bottle. 'It's going be a trillion-dollar market cap, Ken Langone told me that. He's one of the largest investors in Lilly. He knows. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-07-2025
- Business
- Yahoo
Novo Nordisk A/S (NVO): 'Canada's A Backdoor,' Says Jim Cramer
We recently published . Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that was one of the earliest movers in the weight loss drug market. The shares have lost 21% year-to-date due to multiple headwinds. These include investor worries about the firm lagging behind US pharma giant Eli Lilly in the weight loss drug market, the surprise departure of its CEO, and troubles with its CagriSema weight loss drug's trial. Cramer's previous remarks about Novo Nordisk A/S (NYSE:NVO) have wondered why the firm fell behind Eli Lilly and hoped that activist investor interest in the firm would yield positive results. This time around, he discussed the firm's decision to let its weight loss drug patent expire in Canada: 'By the way, nod there to Brandon Gomez, really, really good piece that Novo Nordisk, did not file, I think it's patent correctly in Canada. And Canada's a backdoor, Hims & Hers is right there.' An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. Cramer's previous remarks about Novo Nordisk A/S (NYSE:NVO) discussed the firm's weight loss drug business and activist investor interest: [On activist fund Parvus building a stake in the company] How could they be so far behind? You know they were first, they were first mover. And then Lilly came along, Lilly by the way, still a great stock. But maybe this is going to shake up Novo. While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
